Features of laboratory markers in pregnant women with antiphospholipid syndrome and retrochorial hematoma

Keywords: antiphospholipid syndrome, retrochorial hematoma, antiphospholipid antibodies, antibodies to β2-glycoprotein

Abstract

The aim. Study of hemostasis, antiphospholipid antibody levels and immunological parameters in pregnant women with antiphospholipid syndrome (APS), in particular with retrochorial hematoma (RCH).

Materials and methods. 90 women were selected and divided into two groups: the control group – 30 pregnant women with a normal pregnancy (without APS) and the main group – 60 pregnant women with APS. Women in the main group were diagnosed with APS before pregnancy. In turn, the main group was divided into two subgroups: 1 subgroup – 41 pregnant women without RCH and 2 subgroup – 19 pregnant women with RCH.

The main indicators of hemostasis were determined in all pregnant women, namely: the degree and rate of platelet aggregation, Willebrand factor, D-dimers. In addition, the level of antiphospholipid antibodies (APLA), antibodies to β2-glycoprotein, to annexin V, to prothrombin was examined, and the level of annexin V was also determined. The absolute and relative content of Treg, CD3+, T-lymphocytes, CD4+ (T-helpers), CD8+ (cytotoxic T-lymphocytes), CD19+ (B-lymphocytes), CD16+CD56+ (NK cells), CD16+CD56+CD107a+ (activated NK cells).

Results. The obtained results showed that in pregnant women with APS compared to pregnant women without APS there are statistically significantly higher values of the degree and rate of platelet aggregation (90.6±6.3% and 106.3±6.7% vs. 65.3±5.3 % and 73.4±5.6%, respectively). There were also higher values ​​of Willebrand factor and D-dimers (2.5±0.3 IU/ml and 378.1±34.3 ng/ml against 1.7±0.2 IU/ml and 268.1±27, 3 ng/ml, respectively).

APLAs were significantly higher in pregnant women with APS compared with pregnant women in the control group, namely: 16.1±1.5 vs. 3.8±0.4 U/ml. With regard to antibodies to β2-glycoprotein, to annexin V, to prothrombin and to the level of annexin V, their values were also statistically significantly higher in the group of pregnant women with APS.

In addition, the results of the study showed that pregnant women with APS showed changes in subpopulations of immunocompetent cells.

However, examining the difference in hemostasis, antibody content, and level of lymphocyte subpopulations between pregnant women with APS with and without RCH, it was found that their shifts in pregnant women with RCH were more pronounced than in women without RCH.

Conclusions. Pregnant women with APS are characterized by significantly more significant changes in hemostasis, manifested by activation of intravascular thrombosis. In addition, such pregnant women had a significantly higher concentration of autoantibodies. There are also changes in the immune system, in particular, a decrease in Treg-cells, which have the ability to reduce the specific proliferation and effector functions of lymphocytes, thereby participating in the pathogenesis of APS.

Downloads

Download data is not yet available.

Author Biography

Oleh Tomniuk, Shupyk National Healthcare University of Ukraine

Department of Obstetrics, Gynecology and Perinatology

Ukrainian State Institute of Reproductology

References

Galarza-Maldonado, C., Kourilovitch, M. R., Pérez-Fernández, O. M., Gaybor, M., Cordero, C., Cabrera, S., Soroka, N. F. (2012). Obstetric antiphospholipid syndrome. Autoimmunity Reviews, 11 (4), 288–295. doi: http://doi.org/10.1016/j.autrev.2011.10.006

Garcia, D., Erkan, D. (2018). Diagnosis and Management of the Antiphospholipid Syndrome. New England Journal of Medicine, 378 (21), 2010–2021. doi: http://doi.org/10.1056/nejmra1705454

Schreiber, K., Sciascia, S., de Groot, P. G., Devreese, K., Jacobsen, S., Ruiz-Irastorza, G. et. al. (2018). Antiphospholipid syndrome. Nature Reviews Disease Primers, 4 (1). doi: http://doi.org/10.1038/nrdp.2017.103

Cervera, R. (2017). Antiphospholipid syndrome. Thrombosis Research, 151, S43–S47. doi: http://doi.org/10.1016/s0049-3848(17)30066-x

Antovic, A., Sennström, M., Bremme, K., Svenungsson, E. (2018). Obstetric antiphospholipid syndrome. Lupus Science & Medicine, 5 (1), e000197. doi: http://doi.org/10.1136/lupus-2016-000197

Machin, S. J., Mackie, I. J., Cohen, H., Jayakody Arachchillage, D. R. (2015). Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thrombosis and Haemostasis, 113 (01), 13–19. doi: http://doi.org/10.1160/th14-05-0416

Linnikov, V. I. (2013). Immunotherapy in complex treatment of antyphospholipid syndrome. Tavricheskiy mediko-biologicheskiy vestnik, 16 (2 (1)), 111–116.

Wang, M., Zhang, P., Yu, S., Zhou, G., Lv, J., Nallapothula, D. et. al. (2019). Heparin and aspirin combination therapy restores T-cell phenotype in pregnant patients with antiphospholipid syndrome-related recurrent pregnancy loss. Clinical Immunology, 208, 108259. doi: http://doi.org/10.1016/j.clim.2019.108259

Toffol, E., Koponen, P., Partonen, T. (2013). Miscarriage and mental health: Results of two population-based studies. Psychiatry Research, 205 (1-2), 151–158. doi: http://doi.org/10.1016/j.psychres.2012.08.029

Agenor, A., Bhattacharya, S. (2015). Infertility and Miscarriage: Common Pathways in Manifestation and Management. Women’s Health, 11 (4), 527–541. doi: http://doi.org/10.2217/whe.15.19

Schreiber, K., Hunt, B. (2016). Pregnancy and Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 42 (7), 780–788. doi: http://doi.org/10.1055/s-0036-1592336

Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M. (2012). Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 157 (1), 47–58. doi: http://doi.org/10.1111/j.1365-2141.2012.09037.x

Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A. et. al. (2014). 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity Reviews, 13 (6), 685–696. doi: http://doi.org/10.1016/j.autrev.2014.01.053

Seed, P., Parmar, K., Moore, G. W., Stuart-Smith, S. E., Hunt, B. J., Breen, K. A. (2012). Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thrombosis and Haemostasis, 107 (3), 423–429. doi: http://doi.org/10.1160/th11-08-0554

Schreiber, K., Hunt, B. J. (2019). Managing antiphospholipid syndrome in pregnancy. Thrombosis Research, 181, S41–S46. doi: http://doi.org/10.1016/s0049-3848(19)30366-4

Abrahams, V. M., Chamley, L. W., Salmon, J. E. (2017). Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation. Arthritis & Rheumatology, 69 (9), 1710–1721. doi: http://doi.org/10.1002/art.40136

Lai, Z., Marchena-Mendez, I., Perl, A. (2015). Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. Clinical Immunology, 158 (2), 148–152. doi: http://doi.org/10.1016/j.clim.2015.03.024

Dal Ben, E. R. R., do Prado, C. H., Baptista, T. S. A., Bauer, M. E., Staub, H. L. (2013). Decreased Levels of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Patients with Primary Antiphospholipid Syndrome. Journal of Clinical Immunology, 33 (4), 876–879. doi: http://doi.org/10.1007/s10875-012-9857-y

Soldo, V., Cutura, N., Zamurovic, M. (2013). Threatened miscarriage in the first trimester and retrochorial hematomas: sonographic evaluation and significance. Clin Exp Obstet Gynecol, 40 (4), 548–550.

Sultangadzhieva, K. G., Khizroeva, J. K. (2020). Pathogenetically differentiated management of pregnancy in patients with retrochorial hematoma. Obstetrics, Gynecology and Reproduction, 14 (1), 15–24. doi: http://doi.org/10.17749/2313-7347.2020.14.1.15-24


👁 38
⬇ 53
Published
2021-07-30
How to Cite
Tomniuk, O. (2021). Features of laboratory markers in pregnant women with antiphospholipid syndrome and retrochorial hematoma. EUREKA: Health Sciences, (4), 12-19. https://doi.org/10.21303/2504-5679.2021.001973
Section
Medicine and Dentistry